Nomic Bio Debuts $50 Proteome with Absolute Quantification Through Launch of Omni 1000

For the first time, researchers can access a quantitative proteome-wide solution that profiles 1000 of the most informative proteins at high-throughput.

MONTREAL--(BUSINESS WIRE)--Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform.

Omni 1000 brings together 1,000 rigorously chosen proteins, giving scientists proteome-wide breadth while retaining coverage of hallmark targets with proven utility across drug development and translational applications. The content, designed by combining expert biomarker curation with machine-learning on large annotated proteomic datasets, spans every Level 0 Reactome pathway, all major MeSH disease classes, and pharma-critical KEGG pathways.

By removing traditional barriers to scale, flexibility, and data fidelity in protein measurement, Omni 1000 finally makes proteomics:

• Accessible. With end-to-end pricing as low as $50 per sample, Omni 1000 breaks down economic barriers that previously made proteome-wide profiling out of reach for most scientists. This leap in affordability opens the door to larger, more ambitious initiatives across drug discovery, biomarker validation, and population-wide studies, without compromising analytical power.
• Adaptable. Omni 1000 brings a major expansion to the protein library available for Nomic Flex, which allows researchers to design fully customized panels from the entire target library—without revalidation, hidden fees, or production delays. Together, Nomic Omni and Flex enable a seamless transition from broad discovery to focused verification and validation.
• Absolute. As the first high-plex panel to deliver quantitative clinically relevant data, Omni 1000 empowers more confident decision-making across discovery and translational research. Absolute quantification with Omni ensures full data interoperability—making it possible to build large, unified datasets that drive cross-study insights, target discovery at scale, and proteomic foundational models.

“There’s a lot of exciting progress happening in biology, AI, and healthcare today—but we won’t get as far without large-scale, quantitative proteomic data. In order to better model, understand, and engineer biology, scientists need scalable tools that are accessible enough for broad adoption, and versatile enough for rapid translation,” said Milad Dagher, Co-founder and CEO of Nomic Bio. “The capabilities we’re launching today enable exactly that.”

“Pairing plasma proteomics with health outcomes at scale has the potential to revolutionize the way we treat patients,” said Allie Greenplate, PhD, the director of Strategic Alliance and Operations for Immune Health at the Perelman School of Medicine at the University of Pennsylvania. “We’ve been able to profile our biobank samples, and it’s made proteome-wide analysis more practical for us—both in terms of the cost as well as the ability to get absolute, comparable values across cohorts. That kind of data is much more useful when you’re trying to translate findings across studies or into clinical contexts.”

Omni 1000 marks a major milestone in Nomic’s mission to empower scientists to impact human health and extend lives. By removing the last remaining barriers to high-quality proteomic data—absolute quantification, accessibility, and adaptability—Nomic is making actionable insights available to more teams, and at greater scale, than ever before.

Nomic Omni 1000 is available now as part of Nomic Bio’s end-to-end service platform. Researchers can request access, schedule a demo, or explore additional technical details by visiting nomic.bio.

About Nomic Bio

Nomic was founded to make biology easier to measure and enable scientists to extend lives by making proteomics accessible, scalable, and routine. Powered by its proprietary nELISA^® technology, Nomic delivers large-scale, quantitative, and cost-effective protein data to accelerate discovery, development, and translation. Its end-to-end service combines flexible content, expert support, and analysis-ready outputs—enabling seamless integration of proteomics across all stages of drug and biomarker development. Nomic’s mission is to make proteomics ubiquitous for modern biology. To learn more, visit nomic.bio or follow us on LinkedIn.